Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Is Summit Therapeutics a Buy Now?
04:27am, Tuesday, 10'th Sep 2024
Ivonescimab is a bispecific antibody that targets PD-1 and VEGF to treat lung cancer. In a phase 3 trial, patients treated with ivonescimab were 49% less likely to experience their disease worsening t
Why Summit Therapeutics Rocketed Over 60% Today
02:01pm, Monday, 09'th Sep 2024
Summit's lung cancer treatment Ivonescimab outperformed Merck's Keytruda in a Phase III trial. The data were even better than anticipated.
Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation
12:45pm, Monday, 09'th Sep 2024
Summit's and Akeso's ivonescimab outperformed Merck's Keytruda in a phase 3 trial for first-line advanced NSCLC, showing significant clinical benefits. Ivonescimab's success against Keytruda in NSCLC
Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today
09:57am, Monday, 09'th Sep 2024
Shares of Summit Therapeutics (SMMT) skyrocketed Monday, rising to an all-time high after the biotech announced positive results from a late-stage trial of its experimental lung cancer treatment.
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
09:14am, Monday, 09'th Sep 2024
Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's
Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda
08:06am, Monday, 09'th Sep 2024
Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.
Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring t
First Release of Phase III Head-to-Head Clinical Study Data of Ivonescimab versus Pembrolizumab in NSCLC Ivonescimab Is the First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab in a
Summit Therapeutics Inc. (SMMT) Q2 2024 Earnings Call Transcript
08:55pm, Friday, 09'th Aug 2024
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q2 2024 Results Conference Call August 6, 2024 9:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman and Chie
3 Small-Cap Stocks That Could Outperform the “Magnificent 7”
01:02pm, Thursday, 08'th Aug 2024
Recent headlines have highlighted the shift many investors are making from large-cap to small cap stocks.
Summit Therapeutics May Have Further Upside From Here
05:16am, Saturday, 03'rd Aug 2024
Summit Therapeutics to release second-quarter earnings and operational update on 6 August. Analysts are bullish on Phase 3 trial results for Ivonescimab in September, with a potential de-risking of th
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Wednesday, 03'rd Jul 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street
05:50am, Monday, 17'th Jun 2024
These three stocks have soared between 179% and 220% so far this year. Wall Street thinks they can all jump at least 20% over the next 12 months.
Summit (SMMT) Stock Surges 57% in the Past Month: Here's Why
10:16am, Wednesday, 12'th Jun 2024
Summit Therapeutics (SMMT) surges after data from a late-stage study shows that its experimental antibody beat Merck's Keytruda in a head-to-head setting in treating certain patients with lung cancer.
